Cargando…
Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain
PURPOSE: Histone deacetylase 6 (HDAC6) is a cytoplasmic enzyme that modulates intracellular transport and protein quality control. Inhibition of HDAC6 deacetylase activity has shown beneficial effects in disease models, including Alzheimer’s disease and amyotrophic lateral sclerosis. This first-in-h...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835181/ https://www.ncbi.nlm.nih.gov/pubmed/32638097 http://dx.doi.org/10.1007/s00259-020-04891-y |
_version_ | 1783642459748696064 |
---|---|
author | Koole, Michel Van Weehaeghe, Donatienne Serdons, Kim Herbots, Marissa Cawthorne, Christopher Celen, Sofie Schroeder, Frederick A. Hooker, Jacob M. Bormans, Guy de Hoon, Jan Kranz, Janice E. Van Laere, Koen Gilbert, Tonya M. |
author_facet | Koole, Michel Van Weehaeghe, Donatienne Serdons, Kim Herbots, Marissa Cawthorne, Christopher Celen, Sofie Schroeder, Frederick A. Hooker, Jacob M. Bormans, Guy de Hoon, Jan Kranz, Janice E. Van Laere, Koen Gilbert, Tonya M. |
author_sort | Koole, Michel |
collection | PubMed |
description | PURPOSE: Histone deacetylase 6 (HDAC6) is a cytoplasmic enzyme that modulates intracellular transport and protein quality control. Inhibition of HDAC6 deacetylase activity has shown beneficial effects in disease models, including Alzheimer’s disease and amyotrophic lateral sclerosis. This first-in-human positron emission tomography (PET) study evaluated the brain binding of [(18)F]EKZ-001 ([(18)F]Bavarostat), a radiotracer selective for HDAC6, in healthy adult subjects. METHODS: Biodistribution and radiation dosimetry studies were performed in four healthy subjects (2M/2F, 23.5 ± 2.4 years) using sequential whole-body PET/CT. The most appropriate kinetic model to quantify brain uptake was determined in 12 healthy subjects (6M/6F, 57.6 ± 3.7 years) from 120-min dynamic PET/MR scans using a radiometabolite-corrected arterial plasma input function. Four subjects underwent retest scans (2M/2F, 57.3 ± 5.6 years) with a 1-day interscan interval to determine test-retest variability (TRV). Regional volume of distribution (V(T)) was calculated using one-tissue and two-tissue compartment models (1-2TCM) and Logan graphical analysis (LGA), with time-stability assessed. V(T) differences between males and females were evaluated using volume of interest and whole-brain voxel-wise approaches. RESULTS: The effective dose was 39.1 ± 7.0 μSv/MBq. Based on the Akaike information criterion, 2TCM was the preferred model compared to 1TCM. Regional LGA V(T) were in agreement with 2TCM V(T), however demonstrated a lower absolute TRV of 7.7 ± 4.9%. Regional V(T) values were relatively homogeneous with highest values in the hippocampus and entorhinal cortex. Reduction of acquisition time was achieved with a 0 to 60-min scan followed by a 90 to 120-min scan. Males demonstrated significantly higher V(T) than females in the majority of cortical and subcortical brain regions. No relevant radiotracer related adverse events were reported. CONCLUSION: [(18)F]EKZ-001 is safe and appropriate for quantifying HDAC6 expression in the human brain with Logan graphical analysis as the preferred quantitative approach. Males showed higher HDAC6 expression across the brain compared to females. |
format | Online Article Text |
id | pubmed-7835181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-78351812021-01-29 Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain Koole, Michel Van Weehaeghe, Donatienne Serdons, Kim Herbots, Marissa Cawthorne, Christopher Celen, Sofie Schroeder, Frederick A. Hooker, Jacob M. Bormans, Guy de Hoon, Jan Kranz, Janice E. Van Laere, Koen Gilbert, Tonya M. Eur J Nucl Med Mol Imaging Original Article PURPOSE: Histone deacetylase 6 (HDAC6) is a cytoplasmic enzyme that modulates intracellular transport and protein quality control. Inhibition of HDAC6 deacetylase activity has shown beneficial effects in disease models, including Alzheimer’s disease and amyotrophic lateral sclerosis. This first-in-human positron emission tomography (PET) study evaluated the brain binding of [(18)F]EKZ-001 ([(18)F]Bavarostat), a radiotracer selective for HDAC6, in healthy adult subjects. METHODS: Biodistribution and radiation dosimetry studies were performed in four healthy subjects (2M/2F, 23.5 ± 2.4 years) using sequential whole-body PET/CT. The most appropriate kinetic model to quantify brain uptake was determined in 12 healthy subjects (6M/6F, 57.6 ± 3.7 years) from 120-min dynamic PET/MR scans using a radiometabolite-corrected arterial plasma input function. Four subjects underwent retest scans (2M/2F, 57.3 ± 5.6 years) with a 1-day interscan interval to determine test-retest variability (TRV). Regional volume of distribution (V(T)) was calculated using one-tissue and two-tissue compartment models (1-2TCM) and Logan graphical analysis (LGA), with time-stability assessed. V(T) differences between males and females were evaluated using volume of interest and whole-brain voxel-wise approaches. RESULTS: The effective dose was 39.1 ± 7.0 μSv/MBq. Based on the Akaike information criterion, 2TCM was the preferred model compared to 1TCM. Regional LGA V(T) were in agreement with 2TCM V(T), however demonstrated a lower absolute TRV of 7.7 ± 4.9%. Regional V(T) values were relatively homogeneous with highest values in the hippocampus and entorhinal cortex. Reduction of acquisition time was achieved with a 0 to 60-min scan followed by a 90 to 120-min scan. Males demonstrated significantly higher V(T) than females in the majority of cortical and subcortical brain regions. No relevant radiotracer related adverse events were reported. CONCLUSION: [(18)F]EKZ-001 is safe and appropriate for quantifying HDAC6 expression in the human brain with Logan graphical analysis as the preferred quantitative approach. Males showed higher HDAC6 expression across the brain compared to females. Springer Berlin Heidelberg 2020-07-08 2021 /pmc/articles/PMC7835181/ /pubmed/32638097 http://dx.doi.org/10.1007/s00259-020-04891-y Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Article Koole, Michel Van Weehaeghe, Donatienne Serdons, Kim Herbots, Marissa Cawthorne, Christopher Celen, Sofie Schroeder, Frederick A. Hooker, Jacob M. Bormans, Guy de Hoon, Jan Kranz, Janice E. Van Laere, Koen Gilbert, Tonya M. Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain |
title | Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain |
title_full | Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain |
title_fullStr | Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain |
title_full_unstemmed | Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain |
title_short | Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 in the human brain |
title_sort | clinical validation of the novel hdac6 radiotracer [(18)f]ekz-001 in the human brain |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835181/ https://www.ncbi.nlm.nih.gov/pubmed/32638097 http://dx.doi.org/10.1007/s00259-020-04891-y |
work_keys_str_mv | AT koolemichel clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain AT vanweehaeghedonatienne clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain AT serdonskim clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain AT herbotsmarissa clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain AT cawthornechristopher clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain AT celensofie clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain AT schroederfredericka clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain AT hookerjacobm clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain AT bormansguy clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain AT dehoonjan clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain AT kranzjanicee clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain AT vanlaerekoen clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain AT gilberttonyam clinicalvalidationofthenovelhdac6radiotracer18fekz001inthehumanbrain |